John Fry Email & Phone Number

Irvine, California, United States

Los Angeles County, California, United States

Accomplished oncology drug development and commercialization executive with experience spearheading high-profile global oncology asset development and commercialization programs in both small and large biotech organizations. Solid track record of success leading assets and functional teams in complex matrix environments.Core competencies include:Program leadership & managementTPP development and testingClinical development strategyCross functional asset leadershipCDx partner selection NDA/BLA submission leadershipExecutive / board presentation developmentBusiness developmentAlliance managementCommercial strategy developmentBrand development, positioning, messaging, trade name Commercial launch planning - US/globalPricing StrategyForecasting & asset valuationsLife cycle managementCompetitive intelligence

Irvine, California, United States

Global cross-functional program / operations lead for poziotinib (NSCLC) and eflapegrastim (long-acting G-CSF). Led multiple teams including Development, Preclinical, Regulatory, CMC, Quality, Medical Affairs, Commercial and Access/Reimbursement. Responsible for Driving day-to-day operations with a focus on execution excellence in support of BLA & NDA filings including timely issue identification and resolution. Asset’s primary point of contact with Executive Leadership◾️ Co-authored preliminary request for breakthrough designation. Based on this preliminary request the FDA requested a formal submission.◾️ Lead a multinational team to address time-critical issues in quality management, method validation,and process validation with a foreign CMO that had never undergone a PAI with the FDA. This resulted in a successful PAI with no program delays.◾️ Successfully spearheaded the poziotinib NDA submission, ensuring timely publication of modules and responses to all information requests.◾️ Drove selection of diagnostic partner following rigorous review process and co-led a successful sPMA/CDx submission for poziotinib.◾️ Successfully led eflapegrastim BLA resubmission, ensuring timely responses to all information requests ultimately leading to an FDA approval September 2022.◾️ Conceived and implemented monthly operations review meetings to track progress to corporate goals, highlighting key program issues and proposed mitigation strategies.

Thousand Oaks, California

Pipeline and inline therapeutic strategy lead for investigational assets including poziotinib, eflapegrastin and inline oncology brands including Evomela, Marqibo, Folotyn, and Beleodaq. Led pipeline strategy development, new product planning, TPP development and commercial assessments, forecasting, market research & competitive intelligence. In charge of leadership & coaching of commercial team, annual brand planning & execution.◾️ Successfully led cross-functional pipeline – asset strategy development initiatives, establishing clear and aligned cross-functional plans with gated resourcing.◾️ Communicated recommendations for pipeline assets leading to changes in poziotinib formulation development and initiation of on-body device development for eflapegrastim.◾️ Rebuilt marketing function and commercial operations; implemented annual brand planning processes and tracking process.◾️Adeptly managed commercial team exceeding sales goals for inline brands in ’17, ’18 by 12%, and 15% ◾️Recipient of 2017 Chairman’s Award for outstanding marketing leadership.

Thousand Oaks, California

US commercial launch lead for Evomela in multiple myeloma and US brand lead for Marqibo in ALL (acute lymphoblastic leukemia) Responsible for cross functional launch leadership, cross functional strategy development, Commercial team leadership, coaching and lifecycle planning.◾️ Launched Evomela in multiple myeloma, $160MM US market - core deliverables included brand name and trademark, positioning, promotional messaging, core sales tool development, branded website, pricing strategy, forecast and field force sizing.◾️ Initiated and co-led a prospective observational study that assessed administration time of IV melphalan to the stability of 60 minutes.◾️ Exceeded launch revenue goal for Evomela by 126% with an exit share of 37% after 9 months of sale. (56% YTD, Q2 2017).◾️ Recognized by CEO for outstanding Launch Team Leadership for Evomela – Rising Star Award 2016.◾️ Received outstanding Commercial Leadership Award for Evomela from Ligand Pharmaceuticals in 2017.

Thousand Oaks, California

Led 4 oncology therapeutic pipeline assets from Ph2 through Ph3 and commercial readiness. Global Product Strategy Team Lead responsible for maximizing asset value by enabling successful global development, filing and commercialization.◾️ Co-led multiple therapeutic oncology global product strategy teams to 4 separate global oncology therapeutic registration programs in SCCHN, NSCLC (2) and Gastric Cancer.◾️Successfully Led the Global Commercial Team (GCT), aligning on positioning, branding, messaging, and commercialization/launch strategy. ◾️ Established the rilotumumab and panitumumab global commercial teams (GCT); delivered T-18 global launch plan and forecast - coordinated and led launch readiness activities with archetype countries / markets.◾️ Championed a c-MET biomarker strategy resulting in meaningful competitive differentiation. ◾️Effectively managed strategic alliance with Japanese partner Astellas Pharma. ◾️ Amgen Global Oncology Commercial Lead of the Year Award – 2011.